Home › NDC Lookup › RxCUI directory › RxCUI 2728183

0.5 ML plozasiran 50 MG/ML Prefilled Syringe — RxCUI 2728183

RxNorm drug concept · Semantic clinical drug
RxCUI 2728183 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2728183
Official name0.5 ML plozasiran 50 MG/ML Prefilled Syringe
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asplozasiran 50 MG/ML per 0.5 ML Prefilled Syringe; plozasiran 25 MG in 0.5 ML Prefilled Syringe; plozasiran (as plozasiran sodium) 25 MG per 0.5 ML Prefilled Syringe
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Plozasiran: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It lowers triglycerides in adults with familial chylomicronemia syndrome, an inherited condition that causes very high triglycerides. You use it along with a low-fat diet, not inst...
  • Just once every 3 months, under the skin of your thigh or abdomen. Someone else can use the outer upper arm. We'll make sure you or a caregiver are trained before the first dose.
  • Take it as soon as you remember. Then count 3 months from that date for your next dose.
  • The most common are high blood sugar, headache, nausea, and injection site reactions. Because blood sugar can rise, tell your doctor about symptoms of high blood sugar or if you ha...
📖 Read our full Plozasiran guide →

🕸️ Concept Web — How 0.5 ML plozasiran 50 MG/ML Prefilled Syringe Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 0.5 ML plozasiran 50 MG/ML Prefilled Syringe RxCUI 2728183

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Plozasiran 2727175
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Redemplo 2727342
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Plozasiran Prefilled Syringe 2727340
    • Plozasiran Injectable Product 2727339
    • Plozasiran Prefilled Syringe [Redemplo] 2727345
    • Redemplo Injectable Product 2727344
    • Prefilled Syringe 721656
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Plozasiran 50 MG/ML SCDC · 2727338
  • Plozasiran Prefilled Syringe SCDF · 2727340
  • Plozasiran Injectable Product SCDG · 2727339

Brand-Name Concepts

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 2728183 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
84141-0025-01 1 SYRINGE, GLASS in 1 CARTON (84141-025-01) / 1 mL in 1 SYR... REDEMPLO Arrowhead Pharmaceuticals, Inc. 2025-11-19
Observed labelers: Arrowhead Pharmaceuticals, Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.